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ABSTRACT
Background: The rs738409 C/G single nucleotide polymorphism
in the patatin-like phospholipase domain-containing 3 (PNPLA3;
adiponutrin) leads to a missense mutation (I148M), which is asso-
ciated with increased liver fat but not insulin resistance. The I148M
mutation impedes triglyceride hydrolysis in vitro, and its carriers
have an increased risk of developing severe liver disease.
Objective: We explored whether the rs738409 PNPLA3 G allele
influences the ability of weight loss to decrease liver fat or change
insulin sensitivity.
Design: We recruited 8 subjects who were homozygous for the
rs738409 PNPLA3 G allele (PNPLA3-148MM) and 10 who were
homozygous for the rs738409 PNPLA3 C allele (PNPLA3-148II).
To allow comparison of changes in liver fat, the groups were matched
with respect to baseline age, sex, body mass index, and liver fat. The
subjects were placed on a hypocaloric low-carbohydrate diet for 6 d.
Liver fat content (proton magnetic resonance spectroscopy), whole-
body insulin sensitivity of glucose metabolism (euglycemic clamp
technique), and lipolysis ([2H5]glycerol infusion) were measured be-
fore and after the diet.
Results: At baseline, fasting serum insulin and C-peptide concentra-
tionswere significantly lower in thePNPLA3-148MMgroup than in the
PNPLA3-148II group, as predicted by study design. Weight loss was
not significantly different between groups (PNPLA3-148MM:23.16
0.5 kg; PNPLA3-148II:23.16 0.4 kg). Liver fat decreased by 45% in
the PNPLA3-148MM group (P, 0.001) and by 18% in the PNPLA3-
148II group (P, 0.01).
Conclusion: Weight loss is effective in decreasing liver fat in sub-
jects who are homozygous for the rs738409 PNPLA3 G or C allele.
This trial was registered at www.hus.fi as 233775. Am J Clin Nutr
2011;94:104–11.
INTRODUCTION
Nonalcoholic fatty liverdisease(NAFLD)isarapidlyincreasing
liver disorder covering a range of conditions from simple steatosis
to nonalcoholic steatohepatitis (1). The latter may progress to
cirrhosis (1). Studies in twinshavesuggested that theheritability of
liver enzymes and possibly liver fat inNAFLD is considerable (2).
Recently, Romeo et al (3) identified a single nucleotide poly-
morphism (I148M, rs738409) in the patatin-like phospholipase
domain-containing 3 gene (PNPLA3, adiponutrin) to be highly
significantly associatedwithNAFLD, independent of obesity. The
I148M variant in the adiponutrin gene represents a cytosine (C) to
guanine (G) substitution, which leads to an amino acid change
from isoleucine (I) tomethionine (M) at codon 148 (I148M) in the
PNPLA3 gene. Subjects homozygous for this variant [PNPLA3-
148MM, prevalence’5% (4)] have a liver fat content, measured
by proton magnetic resonance spectroscopy (1H-MRS) (3, 5, 6)
and magnetic resonance imaging (MRI) (7), 1.3–2.4–fold higher
than that of weight-matched homozygous carriers of PNPLA3-
148II. Carriers of PNPLA3-148MM also have a greater incidence
of steatosis, as determined by ultrasound (8) and liver biopsy
analysis (9–13), and more liver fibrosis and inflammation (9–13)
than subjects homozygous for PNPLA3-148II.
Studies in vitro have suggested that the I148M variant abol-
ishes triglyceride hydrolysis, which suggests that PNPLA3-
I148M is a loss-of-function mutation (14). On the other hand,
overexpression of PNPLA3-I148M in mice results in steatosis,
which would suggest that the variant is a gain-of-function mu-
tation (14). There are no data currently available regarding how
and whether the variant influences changes in liver fat in response
to interventions such as weight loss or overfeeding. Given that
many studies have shown carriers of the rs738409 PNPLA3
minor G allele to be at increased risk of severe liver disease, and
that weight loss is perhaps the best treatment of NAFLD, such
a study would seem of clinical relevance (9–13).
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Consistently across all studies, despite higher liver fat content,
insulin sensitivity is not altered in carriers of PNPLA3-148MM
compared with carriers of PNPLA3-148II (3, 5–7). Thus, if
PNPLA3-148MM carriers are matched for liver fat to those with
PNPL3-148II, one would predict the former to be more insulin
sensitive than the latter.
The primary objective of the present study was to compare the
effects of a hypocaloric low-carbohydrate diet on liver fat content
between carriers of PNPLA3-148MM and carriers of PNPLA3-
148II (15). We aimed to achieve similar weight loss in both
groups, which we matched for liver fat at baseline to allow ac-
curate comparison of its changes. We also examined how weight
loss affects whole-body insulin sensitivity of glucose metabolism
and lipolysis measured with [2H5]glycerol in the PNPLA3-
148MM and PNPLA3-148II groups.
SUBJECTS AND METHODS
Subjects and study design
The study subjects were recruited among previously geno-
typed nondiabetic subjects (6). Exclusion criteria included 1)
PNPLA3-148MI variant, 2) type 1 or 2 diabetes, 3) renal in-
sufficiency, 4) preexisting liver or significant other disease other
than NAFLD (ie, autoimmune, viral, or drug-induced liver dis-
ease), 5) excessive use of alcohol (.20 g/d), and 6) pregnancy
or lactation. At baseline, the study groups were matched for age,
sex, body mass index (BMI), and liver fat.
Screening visit
All subjects suitable for the studybasedona telephone interview
were invited to the laboratory for a screening visit. At this visit,
medical histories were collected, physical examinations were
performed, and blood sampleswere collected for themeasurement
of total blood counts, alanine aminotransferase, aspartate ami-
notransferase, alkaline phosphatase, c-glutamyl transferase, total
cholesterol, HDL and LDL cholesterol, triglycerides, bilirubin,
glucose, glycated hemoglobin, insulin, C-peptide, creatinine, al-
bumin, potassium, sodium, prothrombin time, transferrin satura-
tion, antismooth muscle, antinuclear and antimitochondrial
antibodies, and hepatitis A, B, andC serology. A serum pregnancy
test was performed in women of childbearing age. Patients suit-
able for the dietary intervention based on the screening visit were
invited for a metabolic study, which consisted of a baseline visit,
a 6-d hypocaloric low-carbohydrate intervention period, and a final
visit after the diet. Measurements of liver fat content by 1H-MRS
were conductedwithin a day of the clinical visit before and after the
dietary intervention.
Baseline and final visit
At the baseline visit, weight and height were recorded, and
basal blood samples were collected for the measurement of total
blood count, liver function tests, and fasting glucose, insulin, C-
peptide, total cholesterol, HDL and LDL cholesterol, and tri-
glyceride concentrations. After the blood tests were performed,
a needle aspiration biopsy sample was collected from abdominal
subcutaneous adipose tissue (see below). Thereafter, a euglyce-
mic hyperinsulinemic clamp was performed. Blood samples for
measurement of glucose, insulin, free fatty acid (FFAs), and
glycerol concentrations were withdrawn during the clamp (see
below). After the baseline visit, the study subjects were placed
on a standardized hypocaloric (1000-kcal deficit/d) low-carbo-
hydrate (,20 g/d) diet for 6 d. The diet was designed by die-
titians (AR and LS) and provided entirely by the central kitchen
of the Helsinki University Central Hospital. The baseline mea-
surements were repeated after 6 d of the diet. Adherence to the
low-carbohydrate diet was controlled for by verifying development
of ketosis as measured by plasma b-hydroxybutyrate concen-
trations before and after the intervention (see below). All mea-
surements were carried out in the clinical research center, where
patients arrived in the morning after an overnight fast at home.
The purpose, nature, and potential risks of the study were ex-
plained to the subjects before their written informed consent was
obtained. The study protocol was approved by the ethics com-
mittee of the Helsinki University Central Hospital.
Measurement of liver fat content
Liver fat content was measured by using 1H-MRS, as pre-
viously described (16). This measurement has been validated
against histologically determined lipid content (17) and against
estimates of fatty infiltration by computed tomography (18). The
reproducibility of repeated measurements of liver fat in non-
diabetic subjects as determined on 2 separate occasions in our
laboratory is 11% (19).
Whole-body insulin sensitivity of glucose metabolism and
of lipolysis
Whole-body insulin sensitivity of glucose metabolism was
determined by using the euglycemic hyperinsulinemic clamp
technique (20). The duration of the insulin infusion was 120 min,
and the continuous infusion rate was 0.4 mU  kg21  min21 (20).
The low insulin infusion rate was chosen to maximize the like-
lihood of detecting changes in lipolysis. Of note, this infusion
rate is not ideal for measuring the insulin sensitivity of glucose
uptake or suppression of glucose production because the latter
processes have dose-response characteristics very different from
those of insulin compared with lipolysis (21, 22). The rate of
whole-body lipolysis and the effect of insulin on lipolysis were
determined by infusing [2H5]glycerol, which was infused for
120 min before and for 120 min during the insulin infusion (start
of insulin infusion = time point 0). Before the infusions began,
two 18-gauge catheters (Venflon; Viggo-Spectramed, Helsing-
borg, Sweden) were inserted: one in a left antecubital vein and
another retrogradely in a heated (+65C) dorsal hand vein for
sampling of arterialized venous blood for insulin (2120,260, 0,
30, 60, 90, and 120 min), FFAs (2120, 260, 230, 0, 10, 15, 20,
25, 30, 45, 60, and 120 min), b-hydroxybutyrate (2120, 260, 0,
15, 30, 45, 60, and 120 min), and glycerol and its isotopic en-
richment (2120, 230, 220, 210, 0, 10, 15, 20, 25, 30, 45, 60,
90, and 120 min). Glycerol, insulin, and glucose were infused
into the antecubital vein. The whole-body insulin sensitivity of
glucose metabolism was determined from the glucose infusion
rate required to maintain euglycemia corrected for glucose pool
size (M-value) during the insulin infusion (0–120 min). Mea-
surement of lipolysis (glycerol rate of appearance; Ra) was
technically unsuccessful in one patient (patient included in all
other analyses).
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Indirect calorimetry
Respiratory gas exchange and resting energy expenditure were
recorded for 40min before the insulin infusion (270 to230min)
and for 40min during euglycemic hyperinsulinemia (75–115min)
by indirect calorimetry using a computerized flow-through
canopy system (Deltatrac metabolic monitor; Datex, Helsinki,
Finland) as described previously (23). Protein oxidation was es-
timated from urinary urea nitrogen excretion (23). Rates of car-
bohydrate and lipid oxidation and total energy expenditure were
calculated from thegas exchange data as previously described (23,
24). Because ketone body production and utilization after the
ketogenic diet can be predicted to influence indirect calorimetry
calculations (24), only data on nonprotein respiratory quotient
(NPRQ) are given after the diet.
Subcutaneous fat biopsy samples
To determine whether weight loss influences PNPLA3 ex-
pression, a needle aspiration biopsy sample of subcutaneous ad-
ipose tissue was collected under local anesthesia with lidocaine at
baseline and at the completion of the study. The adipose tissue
sample was immediately frozen in liquid nitrogen until analyzed.
Quantitative real-time reverse transcriptase polymerase
chain reaction analysis of mRNA expression
Total RNAwas isolated by using the RNeasyMini Kit (Qiagen,
Valencia, CA). The RNAs (1000 ng) were reverse transcribed by
using the SuperScript VILO cDNA synthesis kit (Invitrogen/Life
Technologies, Carlsbad, CA). Each sample was amplified in du-
plicate (in 2 independent experiments) for the gene of interest and
the housekeeping marker 36B4 on a 7000 Sequence Detection
System(AppliedBiosystems/LifeTechnologies,Carlsbad,CA)by
using themanufacturer’s SYBR-Green kit. Relative quantification
for thegeneof interestwascarriedoutbyusingnormalization to the
36B4 mRNAvalues. The following primers were used: PNPLA3,
5#-CTGTACCCTGCCTGTGGAAT-3# (sense) and 5#-TCGAGTG-
AACACCTGTGAGG-3# (antisense); 36B4, 5#-CATGCTCAACAT-
CTCCCCCTTCTCC-3# (sense) and 5#-GGGAAGGTGTAATCC-
GTCTCCACAG-3# (antisense).
Analytic procedures
Plasmaglucose concentrationsduring the clampweremeasured
in duplicate with the glucose oxidase method by using Beckman
Glucose Analyzer II (Beckman Instruments, Fullerton, CA). For
screeningpurposes, fastingplasmaglucosewasmeasuredbyusing
a hexokinase method on an autoanalyzer (Roche Diagnostics
Hitachi 917; Hitachi Ltd, Tokyo, Japan). Serum insulin and
C-peptide concentrations were measured by time-resolved fluo-
roimmunoassay with the use of Insulin and C-peptide kits
(AUTOdelfia; Wallac, Turku, Finland), respectively. Glycated
hemoglobin was measured by HPLC with a fully automated
Glycosylated Hemoglobin Analyzer System (BioRad, Richmond,
CA). Serum total and HDL cholesterol and triglyceride concen-
trationsweremeasuredwith respective enzymatic kits fromRoche
Diagnostics by using an autoanalyzer (Roche Diagnostics Hitachi
917). Serum alanine aminotransferase, serum aspartate amino-
transferase, and plasma creatinine concentrations were measured
as recommended by the European Committee for Clinical Labo-
ratory Standards. SerumC-reactive protein was analyzed by using
a commercial kit (Ultrasensitive CRP Kit; Orion Diagnostica,
Espoo, Finland). Ketone bodies were measured with the use of
aphotometricmethodwithanOlympusAU640analyzer (Olympus
Corporation, Shizuoka, Japan). Urea concentrations in urine were
measured by using an enzymatic photometric assay (Roche
Diagnostics)withaModularAnalyzer (HitachiLtd,Tokyo,Japan).
FFAs were measured by using an enzymatic colorimetric as-
say [NEFA-HR (2); Wako Chemicals GmbH, Neuss, Germany]
with a Konelab 60i analyzer (Thermo Electron Corporation,
Vantaa, Finland). [2H5]Glycerol enrichment was measured by gas
chromatography–mass spectrometry (GC-MS) as previously de-
scribed (25). Briefly, after deproteinization, plasma sample were
derivatized with pyridine and acetic anhydride (1:1) and then re-
constitutedwith ethyl acetate (80 lL). Samples were then injected
(2 lL) in the GC-MS (Agilent, Palo Alto, CA), and enrichment
was evaluated as the peak area ratio between fragments of mass
148 and 145, after correction for baseline values. During the last
20 min of the tracer equilibration period, both plasma glycerol
concentrations and [2H5]glycerol enrichments were stable in all
subjects. Therefore, the Ra of endogenous glycerol was calculated
as the ratio of the tracer infusion rate to the plasma tracer en-
richment (mean of 3 determinations). During the clamp, glycerol
Ra was calculated from [
2H5]glycerol enrichment by using
Steele’s equation (25).
Statistical analyses
Demographic and clinical characteristics of the study groups
at baseline were compared by using Fisher’s exact test for cat-
egorical variables and unpaired t test for continuous variables.
Distribution of continuous variables was tested for normality
by using a Kolmogorov-Smirnov test, and, because the studied
variables were normally distributed, the use of a parametric t test
was justified. To analyze the effect of dietary intervention on the
study groups with different genotypes and the potential in-
teraction between the 2 factors, we used 2-factor analysis of
variance for repeated measures with Bonferroni post hoc tests
for the analysis of the effect of time. For variables significantly
different between the groups at baseline, we used analysis of
covariance to adjust for the baseline values when calculating the
final significance of change due to the dietary intervention.
Correlations were calculated as exploratory analyses on the data
post hoc by using Spearman’s rank correlation coefficient. For
the statistical analyses, GraphPad Prism version 4.03 (GraphPad
Software Inc, San Diego, CA), SYSTAT version 10 (SPSS Inc,
Chicago, IL), and Lotus 1–2-3 (Lotus SmartSuite Release 9.5;
Lotus Development Corporation, IBM Corporation, New York,
NY) were used. The data are reported as means 6 SEMs. Two-
tailed P values ,0.05 were considered significant.
RESULTS
Baseline characteristics
The clinical and biochemical characteristics of the study
groups are summarized in Table 1. At baseline, the groups were
comparable with respect to sex, age, weight, BMI, and liver fat
content. Fasting serum insulin and C-peptide concentrations at
baseline were significantly lower in the PNPLA3-148MM group
than in the PNPLA3-148II group (Table 1).
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Body weight
In all subjects, body weight decreased from 89.56 4.6 to 86.46
4.4 kg (P, 0.001). Body weight and percentage loss of body weight
decreased significantly and similarly in both groups: 23.1 6 0.5 kg
and 23.7 6 0.5% in the PNPLA3-148MM group and 23.1 6 0.4
kg and 23.3 6 0.3% in the PNPLA3-148II group (Figure 1A).
Liver fat
In the entire group, liver fat decreased by 30.06 6.1%, from 11.1
6 1.4% at baseline to 8.4 6 1.4% after the 6-d diet (P , 0.001).
Liver fat content decreased in the PNPLA3-148MM group by 44.6
6 7.0%, from 10.1 61.8% to 6.5 6 1.7% (P , 0.001), and in the
PNPLA-148II group by 18.4 6 7.8%, from 11.9 6 2.1% to 9.9 6
2.0% (P, 0.01) (Figure 1B). Also, the absolute change in liver fat
was significantly greater in the PNPLA3-148MM group than in the
PNPLA3148II group (23.76 0.5% compared with22.06 0.6%;
P = 0.042; Figure 1C). The percentage change in liver fat was sig-
nificantly higher in the PNPLA3-148MMgroup than in the PNPLA3-
148II group (P = 0.027; Figure 1D). The absolute and percentage
decreases in liver fat were also statistically significant if the baseline
liver fat contentwas included in theanalysis as a covariate (P=0.03).
Serum alanine aminotransferase did not change significantly from
before to after the diet in the PNPLA3-148MM group (from 446
11 to 446 9U/L) or in the PNPLA3-148II group (from 616 17 to
616 13 U/L). Similarly, no significant changes were seen in aspar-
tate aminotransferase, alkaline phosphatase, or c-glutamyltransferase
concentrations in either group (data not shown).
Fasting serum insulin and whole-body insulin sensitivity of
glucose metabolism
In all subjects, fasting serum insulin decreased significantly
after the diet, from 10.1 6 1.4 to 6.4 6 1.1 mU/L (P , 0.001).
The decrease was significant in both the PNPLA3-148MM (P ,
0.05) and PNPLA3-148II (P , 0.0001) groups (Table 1).
During the insulin infusion, steady state serum insulin con-
centrations (30–120 min) for all subjects were similar before
(24.5 6 2.1 mU/L) and after (23.9 6 1.5 mU/L) the diet (P =
0.69), and no differences were observed between the PNPLA3-
148MM and PNPLA3-148II groups (data not shown).
In the entire group, whole-body insulin sensitivity of glucose
metabolism (M-value) increased from 0.86 0.1 to 1.16 0.2 mg
 kg21  min21 (P = 0.02). The effect of time was statistically
significant (P = 0.01), whereas the time · genotype interaction
was not statistically significant (Figure 2).
Plasma b-hydroxybutyrate and serum FFA concentrations
and whole-body insulin sensitivity of lipolysis
In all subjects, fasting plasma b-hydroxybutyrate concen-
trations increased 5.4-fold, from 0.176 0.02 before to 0.936 0.2
mmol/L after the diet (P, 0.0005). After the diet, fasting plasma
b-hydroxybutyrate concentrations increased significantly in the
PNPLA3-148MMgroup from 0.166 0.01 to 1.006 0.28mmol/L
(P , 0.01) and in the PNPLA3-148II group from 0.15 6 0.01 to
0.62 6 0.18 mmol/L (P , 0.05) (Figure 3, A and B). No signif-
icant effect of genotype on b-hydroxybutyrate concentrations was
observed, either basally or during hyperinsulinemia or in response
to insulin either before or after the diet at any time point (Figure 3,
A and B).
In all subjects, fasting serum FFAs increased from 540 6 35
lmol/L before to 750 6 35 lmol/L after the diet (P = 0.0001).
The changes in serum FFAs by the diet and by insulin were
similar between the PNPLA3-148MM and PNPLA3-148II
groups (Figure 3, C and D).
The sensitivity of lipolysis to insulin increased in all subjects,
because the percentage suppression of glycerol Ra (lipolysis) by
insulin was significantly higher after (48.9 6 2.6%) than before
(36.1 6 4.3%) the diet (P = 0.002). The percentage suppression
was enhanced by the ketogenic diet in the PNPLA3-148MM
group (376 5% before and 51 6 4% after; P , 0.05) and in the
PNPLA3-148II group (35 6 7% before and 47 6 4% after; P .
TABLE 1
Characteristics of the study subjects1
PNPLA3-148MM
(n = 2 M, 6 F)
PNPLA3-148II
(n = 4 M, 6 F)
Two-factor repeated-
measures ANOVA
Before After Before After Time Time · genotype
Age (y) 48 6 4 52 6 4
Body composition
Weight (kg) 85 6 7 82 6 7 93 6 6 90 6 6 ,0.0001 0.95
BMI (kg/m2) 29.6 6 2.2 28.4 6 2.1 30.7 6 2.0 29.7 6 1.9 ,0.0001 0.66
Liver fat (%) 10.2 6 1.8 6.5 6 1.7zz 11.9 6 2.1 9.9 6 2.0z ,0.0001 0.04
Biochemical variables, fasting
Plasma glucose (mg/dL) 100 6 3 84 6 5 102 6 4 96 6 4 0.002 0.14
Serum insulin (mU/L) 6.9 6 1.3* 4.3 6 1.1 12.6 6 2.0 8.0 6 1.1 ,0.0001 0.122
Serum C-peptide (nmol/L) 0.7 6 0.1* 0.4 6 0.1 1.1 6 1.2 0.8 6 0.1 ,0.0001 0.372
Serum LDL cholesterol (mmol/L) 3.0 6 0.5 3.2 6 0.5 3.2 6 0.2 3.2 6 0.3 0.25 0.52
Serum HDL cholesterol (mmol/L) 1.5 6 0.1 1.5 6 0.2 1.2 6 0.1 1.1 6 0.1 0.57 0.41
Serum triglycerides (mmol/L) 1.2 6 0.3 0.8 6 0.1 1.6 6 0.2 0.9 6 0.1 0.0002 0.30
1 All values are means 6 SEMs. *Significantly different from PNPLA3-148II at baseline, P , 0.05 (unpaired t test).
z,zzSignificantly different from “Before” (Bonferroni post hoc test for the within-group effect of time): zP , 0.01, zzP ,
0.001.
2 The decrease in serum insulin and C-peptide concentrations was not significantly different between the study groups
after considering the respective baseline values as covariates in the analysis.
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0.05). No statistical difference, however, was found between the
groups with respect to the degree of change in suppression of
lipolysis.
Rates of substrate oxidation and energy expenditure
At baseline in all subjects, insulin increased the NPRQ from
0.736 0.02 to 0.776 0.02 (P = 0.03), and carbohydrate oxidation
increased from 0.256 0.13 to 0.536 0.16 mg  kg21 min21 (P =
0.004). Acute hyperinsulinemia decreased lipid oxidation from
1.02 6 0.06 to 0.91 6 0.08 mg  kg21  min21 (P = 0.007) in all
subjects. The responses to insulin before the diet did not differ
between the study groups.
In all subjects, the rate of protein oxidation was similar before
(0.59 6 0.07 mg  kg21  min21) and after (0.64 6 0.07 mg 
kg21  min21) the diet. Protein oxidation rates were comparable
between the groups both before and after the diet (data not
shown). The NPRQ was significantly lower after the diet (0.67
6 0.01) than before the diet (0.73 6 0.02) in all subjects (P =
0.0001). The PNPLA3 genotype did not influence the change in
NPRQ.
Correlates of changes in liver fat during the diet
We calculated the correlation coefficients between changes in
liver fat and insulin sensitivity of glucosemetabolismwith those of
serum FFA concentrations and glycerol fluxes. The antilipolytic
effects of insulin, measured as percentage (absolute data not
shown) suppression of serum FFA, correlated with the M-value
both before (q=20.67,P=0.002) and after (q=20.75,P=0.003)
the diet. The percentage change in liver fat correlated significantly
with the change in absolute glycerol Ra during hyperinsulinemia
(q = 0.53, P = 0.028).
PNPLA3 mRNA and protein expression
PNPLA3 mRNAwas detectable in all adipose tissue samples.
In all subjects, expression of the PNPLA3 gene decreased by
27% after the diet (P = 0.044, Figure 4). PNPLA3 expression
did not differ significantly between the PNPLA3-148MM and
PNPNLA3-148II groups either before or after the diet (data not
shown).
DISCUSSION
Summary
The rs738409minorG allele of PNPLA3 has been suggested to
impair triglyceride hydrolysis in in vitro studies (14). Recently, 5
independent studies have shown that homozygous carriers of this
allele have an increased risk of nonalcoholic steatohepatitis (9–
13), for which weight loss is currently considered the perhaps best
treatment (26). We therefore reasoned that it would be important
FIGURE 2. Mean (6SEM) whole-body insulin sensitivity of glucose
metabolism (M-value) before and after the dietary intervention in the
PNPLA3-148MM (n = 8) and PNPLA3-148II (n = 10) genotype groups.
Two-factor ANOVA for repeated measures was used for data analysis with
Bonferroni post hoc test for the effect of time. Effect of time: P = 0.01. Time
· genotype interaction: P = 0.15.
FIGURE 1.Mean (6SEM) change in body weight as measured by scale (A) and change in liver fat content (B), absolute change in liver fat content (C), and
percentage change in liver fat content (D) as measured by proton magnetic resonance spectroscopy (1H-MRS) after a 6-d hypocaloric, low-carbohydrate diet in
the PNPLA3-148MM (n = 8) and PNPLA3-148II (n = 10) genotype groups. Unpaired t test and 2-factor ANOVA for repeated measures were used for data
analysis with Bonferroni post hoc test for the effect of time, as appropriate. *P , 0.05, **P , 0.01, ***P , 0.001.
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to establish whether weight loss is able to decrease liver fat in
homozygous carriers of the rs738409G allele (PNPLA3-148MM
group). In response to a 6-d hypocaloric low carbohydrate diet,
both groups lost similar amounts of body weight and ketone body
concentrations increased in a comparable manner. Liver fat con-
tent decreased significantly more both in absolute and relative
units in the PNPLA3-148MM than the PNPLA3-148II group.
These data show that weight loss is an effective means for re-
ducing liver fat content in subjects with PNPLA3-148MM.
Selection and matching of subjects
Previous studies have found liver fat content to be significantly
(1.3–2.4 -fold) higher but fasting insulin concentrations similar in
carriers of PNPLA3-148MM as compared with PNPLA3-148II
(3, 5–7). In the present study, we compared groups with similar
baseline liver fat content to allow reliable comparison of its
changes during a hypocaloric low carbohydrate diet. This
matching resulted, expectedly, in a baseline difference in insulin
sensitivity as measured using fasting insulin concentrations.
Liver fat decreased significantly more in absolute and relative
units in subjects with PNPLA3-148MM compared with those
with PNPLA3-148II. Because PNPLA3-148M appears to pro-
mote intrahepatocellular triglyceride accumulation by either
inhibiting triglyceride hydrolysis or promoting de novo lipo-
genesis (see below), the differential response in liver fat is, as
discussed below, more likely to be related to the baseline differ-
ence in insulin sensitivity than to the PNPLA3 mutation per se.
Change in lipolysis, ketones, and NPRQ in the entire group
In the present study, we measured whole-body rates of li-
polysis, as at least 2 large studies have shown that serum FFA are
closely correlated with liver fat content under hyperinsulinemic,
but not fasting conditions (27, 28). Because lipolysis is sup-
pressed by very low insulin concentrations even in insulin-re-
sistant subjects (21, 29, 30), we chose a low insulin infusion dose
FIGURE 3. Mean (6SEM) plasma b-hydroxybutyrate concentrations (A and B), serum free fatty acid concentrations (S-FFA; C and D), and rate of
appearance (Ra) of glycerol (E and F) during the euglycemic hyperinsulinemic clamp before (A, C, and E) and after (B, D, and F) the dietary intervention in
the PNPLA3-148MM (d; n = 8) and PNPLA3-148II (s; n = 10 for b-hydroxybutyrate and FFA, and n = 9 for glycerol Ra) genotype groups. Two-factor
ANOVA for repeated measures was used for data analysis. None of the data points differ significantly between the PNPLA3-148MM and the PNPLA3-148II
groups.
FIGURE 4.Mean (6SEM) percentage change from baseline (set to equal
100%) in PNPLA3 mRNA concentrations. n = 18. *Significant difference
between before and after the diet, P , 0.05 (unpaired t test).
PNPLA3, WEIGHT LOSS, AND LIVER FAT 109
 at UNIV O
F TEXAS HEALTH SCIENCE CENTER AT SAN ANTO
NIO
 (UTHSC) on August 17, 2011
w
w
w
.ajcn.org
D
ow
nloaded from
 
to prevent complete suppression of lipolysis. We found the low
carbohydrate ketogenic diet to decrease serum insulin and in-
crease FFA concentrations significantly and similarly in both
groups. The increase in FFA provides fuel for maintenance of
gluconeogenesis and ketogenesis during carbohydrate restriction
(31). Consistent with enhanced lipid or ketone body oxidation,
the NPRQ decreased significantly. In the entire group, the sen-
sitivity of lipolysis to insulin, measured as the % suppression of
either FFA or glycerol Ra by insulin increased significantly
(Figure 3). These data are novel as we are not aware of studies
measuring in vivo rates of lipolysis before and after weight loss
in humans. Enhanced insulin suppression of FFA after weight
loss has been observed in our own previous study and that of
Kelley et al (32, 33).
These are the first data directly quantifying the rate of in vivo
lipolysis in homozygous carriers of rs738409 PNPLA3 variants
(PNPLA-148MM and PNPL3-148II). A recent cross-sectional
study by Santoro et al (34) reported glycerol turnover rates
between the carriers of PNPLA3-148II and “G allele carriers”
(ie, PNPLA3-148IM and/or PNPLA3-148MM) in 41 obese
subjects matched for BMI, but not liver fat. As in the present
study, no difference was observed in insulin sensitivity of li-
polysis between the study groups.
Although we found no significant difference in rates of li-
polysis between the groups, there was a significant correlation
between the change in lipolysis measured with [2H5]glycerol
during hyperinsulinemia and the change in liver fat content.
Because peripheral lipolysis is the major source of intra-
hepatocellular triglycerides both under fasting and postprandial
conditions (35), this result suggests that the greater decrease in
liver fat in the PNPLA3-148MM group was due to a change in
insulin action on FFA delivery to the liver. As insulin action on
lipolysis and the M-value were highly significantly correlated
before and after the diet, the greater insulin sensitivity of the
PNPLA3-148MM than the PNPLA3-148II group could have
contributed to the greater decrease in liver fat.
Thewhole-body glucose infusion rate corrected for changes in the
glucose pool size (the M-value) tended to increase more in the
PNPLA3-148MM than the PNPLA3-148II group. The greater in-
crease, in view of the low insulin concentration used, is likely
to reflect greater improvement in hepatic insulin sensitivity due
to greater loss of liver fat in the PNPLA3-148MM than the
PNPLA3-148II group. This interpretation is supported by data of
Kirk et al (15), who using a similar hypocaloric ketogenic diet, found
an improvement in hepatic but not peripheral insulin sensitivity.
De novo lipogenesis
After peripheral lipolysis, de novo lipogenesis is quantitatively
the second most important source of intrahepatocellular trigly-
cerides inNAFLD (35, 36). Insulin stimulates de novo lipogenesis
via liver X receptor (LXR) and the sterol regulatory element
binding protein 1c (SREBP1c) (37, 38). In rodent models, this
pathway has been suggested to be unaffected by insulin resistance
leading to its stimulation in hyperinsulinemic animals (39). The
45% lower insulin concentration in the PNPLA3-148MM than the
PNPLA3-148II group (Table 1) could, therefore, have been as-
sociated with a lower rate of de novo lipogenesis, but this possi-
bility was not directly explored.
Adipose tissue and liver PNPLA3
Consistent with other SREBP1c-activated genes, PNPLA3 is
strongly upregulated by insulin and refeeding (40–44). One
would, therefore, expect weight loss to decrease PNPLA3 ex-
pression. This was found in adipose tissue but the sample size is
too low to allow conclusions regarding effects of the PNPLA3
genotype on changes in PNPLA3 gene expression.
We conclude that weight loss is an effective way to decrease
liver fat irrespective of the PNPLA3 genotype. Indeed, short-term
weight loss decreases liver fat content even more in homozygous
carriers of PNPLA3-148MM than in those carrying PNPLA3-
148II. Because the PNPLA3-148MM genotype predisposes its
carriers to severe liver disease (9–13), these patients might be
those particularly benefiting from weight loss–induced decrease
in liver fat.
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